CYNK-101 placental NK cell therapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma
phase 1drug program · high · Thu Apr 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Test whether placental CD34+ cell-derived NK cells can be safely combined with trastuzumab and pembrolizumab-based first-line therapy for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Dose-finding clinical trial of CYNK-101 with trastuzumab and pembrolizumab after induction chemotherapy in HER2-positive G/GEJ adenocarcinoma.
Clinical trial published on ClinicalTrials.gov to determine maximum tolerated dose and evaluate safety.
CYNK-001 placental NK cell therapy
phase 2drug program · high · Wed Sep 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate placenta-derived culture-expanded natural killer cells as an allogeneic immunotherapy across recurrent glioblastoma, acute myeloid leukemia, multiple myeloma, and COVID-19.
Clinical trials administering NK cells derived from human placental CD34+ cells, including IV, intracavitary, or intratumoral administration, sometimes after lymphodepleting chemotherapy or with recombinant human IL-2.
Multiple clinical trials listed, including a Phase 1/2a recurrent IDH1 wild-type glioblastoma study assessing safety, feasibility, dose, and PFS6M.
Flowable decellularized human placental connective tissue matrix for alveolar ridge preservation
exploratoryother · high
Improve soft-tissue and bone preservation after tooth extraction to support alveolar ridge preservation and implant placement.
Split-mouth randomized pilot study comparing allograft mixed with flowable decellularized human placental connective tissue matrix versus allograft alone, with clinical, digital scan, photographic, and cone-beam CT follow-up.
2025 pilot study published in Dentistry Journal.
Ten patients completed the study. HPCTM-treated sites showed reduced gingival shrinkage at days 10, 21, and 30, and less radiographic bone-volume loss than controls at 4 months.
PDA-002 placenta-derived cells for diabetic foot ulcers with peripheral artery disease
phase 2drug program · high
Treat chronic diabetic foot ulcers, including patients with peripheral artery disease, by promoting angiogenesis and tissue regeneration.
Phase 2 multicenter randomized double-blind placebo-controlled trial of intramuscular human placenta-derived mesenchymal stromal cell-like cells at 3, 10, or 30 million cells versus placebo.
Phase 2 results published reporting wound-closure outcomes in diabetic foot ulcer patients with and without peripheral artery disease.
PDA-002 was well tolerated with no treatment-related serious adverse events. The 3 million cell dose showed the highest efficacy in the peripheral artery disease subgroup, with 38.5% complete wound closure versus 22.6% for placebo using a 4-week durability endpoint.
Placenta-derived exosome therapy for osteoarthritis
preclinicaldrug program · medium
Evaluate human placenta-derived exosomes as a potential disease-modifying therapeutic for osteoarthritis.
Generation of exosomes from full-term human placenta tissue by sequential centrifugation, purification, and sterile filtration, followed by characterization and therapeutic evaluation for osteoarthritis.
Publication describes characterization of human placenta-derived exosomes as an osteoarthritis therapeutic candidate.
Placental circulating T-cell allogeneic CAR-T platform
preclinicalplatform · high
Develop placental circulating T cells as a source for allogeneic CAR-T products with improved stemness, cytokine profile, persistence, and durability versus adult PBMC-derived CAR-T cells.
Comparative preclinical generation and characterization of CAR-T cells from placental circulating T cells versus adult PBMC T cells using flow cytometry, functional assays, RNA sequencing, and a Daudi lymphoma xenograft model.
2024 publication reported preclinical characterization and in vivo lymphoma efficacy for placental circulating T-cell CD19 CAR-T cells.
Placental T-cell CD19 CAR-T cells retained naive and stem-like features, had longer telomeres, resisted checkpoint upregulation and differentiation, produced less interferon gamma, and eliminated lymphoma beyond 90 days in mice, while PBMC-derived CD19 CAR-T had non-durable benefit.
PNK-007 cord-blood-derived NK cell therapy for multiple myeloma
phase 1drug program · medium
Assess the acceptable dose and timing of culture-expanded NK cell infusion after autologous stem cell transplant in multiple myeloma.
Clinical safety study of human cord-blood-derived culture-expanded NK cells, with or without subcutaneous recombinant human IL-2, following autologous stem cell transplant.
Clinical trial record describes dose and timing evaluation after autologous stem cell transplant.
